OVERVIEW

Surviving and Thriving with B-Cell Malignancies: Surveying an Ever-Evolving Landscape is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Oct 31, 2018 - Oct 31, 2019.

Target Audience:
Designed for hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (e.g., physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants) who are involved and/or interested in the treatment of patients with hematologic malignancies.

Accreditation:
CME:
NACCME designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™.

Physican Assistants:

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 0.75 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 credit(s).

CNE
This continuing nursing education activity awards 0.75 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 0.75 contact hours.

CPE
This knowledge-based activity (JA0006201-9999-18-209-H01-P) is approved for 0.75 contact hours (0.0075 CEUs) of continuing pharmacy education.

Course Overview:
Classification, staging, and treatment strategies for B-cell malignancies have progressed rapidly over the last 2 decades, as have their treatments, evolving from traditional standards of chemotherapy, radiation therapy and/or stem cell transplantation, to a more focused targeted-treatment approach that capitalizes on recent discoveries of molecular surface expressions and cell signaling pathways that are common to diseased B-cells. In 2018, B-cell malignancies are likely to be treated with a combination of chemotherapy,targeted treatments, and/or newer and emerging immunotherapies such as monoclonal antibodies, immune checkpoint inhibitors (ICIs), and chimeric antigen receptor T-cell (CAR-T) therapy. Newer cell-signaling inhibitors are also increasingly being used for B-cell malignancies. This introduces a tantalizing array of novel and unfamiliar treatment options that many hematology-focused clinicians are still unacquainted with.

This on-demand web archive is initiated to address knowledge and practice gaps among physicians, NPs, and PAs pertaining to latest strategies for diagnosing and treating patients with B-cell malignancies.

Course Objectives:
• Analyze revisions in classification, staging, and risk stratification of various NHL subtypes and CLL/SLL
• Identify genetic aberrations, cellular expressions, and cell signaling pathways that are common to malignant B-cell diseases
• Differentiate between the mechanisms of action and efficacy/safety profiles of immunotherapies for B-cell malignancies including monoclonal antibodies, ICIs, and CAR-T
• Address barriers against implementation of newer or emerging therapeutic options for B-cell malignancies

Additional details will be posted as soon as they are available.